Fatal Case Of Solid Organ Infarcts In a Case Of Myelodysplastic Syndrome (MDS) With Refractory Anaemia


  •   Kolluru Karthik Raja

  •   Yash Gupte

  •   Parth Godhiwala

  •   Sharad Sonawane

  •   Shilpa Gaidhane

  •   Sunil Kumar

  •   Quazi syed Zahiruddin


Myelodysplastic syndrome (MDS) usually presents with cytopenias  because of bone marrow failure. Solid organ infarcts in myelodysplastic syndrome (MDS) is rarest complication. We report an elderly male, admitted with complaints of pain abdomen mainly in both flanks and swelling all over the body. Peripheral  blood smear, bone marrow aspirate for cytology were suggestive of myelodysplastic syndrome(MDS) with refractory anaemia. Fluorescence in situ hybridization(FISH) were negative for any chromosomal abnormalities. His CECT abdomen was done which revealed hepatosplenomegaly with hyperdense liver with multiple splenic and renal infarcts and patient was treated as a case of MDS with refractory anaemia with solid organ infarcts. Over a period of 3 days, he had Acute Kidney Injury (AKI).  Patient succumbed on fifth day.

Keywords: Myelodysplastic syndrome (MDS), renal infarct, splenic infarct, a case report.


Dansey R. Myelodysplasia. Curr. Opin. Oncol. 2000; 12: 13–21 [Crossref], [PubMed], [Web of Science ®], [Google Scholar]

Lowenthal R.M., Marsden K.A. Myelodysplastic syndromes. Int. J. Hematol. 1997; 65: 319–338 [Crossref], [PubMed], [Web of Science ®], [Google Scholar]

Mittelman M., Zeidman A. Platelet function in myelodysplastic syndromes. Int. J. Hematol. 2000; 71: 95–98 [Google Scholar]

Swarna Sri Nalluru, Vishal Jindal, Paramarajan Piranavan, Yugandhara Kate, and Ahmad D. Siddiqui, Splenic infarction secondary to myelodysplastic syndrome: unravelling more etiologies.

Hyun Woo Bae, Hyun Dong Kim, Sung Won Choi, Nami Han, Mi Ja Eom, Acute Cerebral Infarction as a Rare Thrombotic Event in Myelodysplastic Syndrome: A Case Report.

MN Niazy*, TI Neyyarapally**, A Chattopadhyay***Erythropoietin-Induced Deep Vein Thrombosis in Myelodysplastic Syndrome.

Wurthner, J.U.;kohler,G.;Behringer, D.;Lindemann, A.; Mertelsmann, R.;Lubbert, M. Leukostasis followed by haemorrhage complicating the initation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis. Cancer 1999,85, 368-374

Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood. 2002;100:4427–4432. [PubMed] [Google Scholar]

Labardini JR, Hernández MC, Cervera E, et al., “Síndromes mielodisplásicos”. Instituto Nacional de Cancerología, vol.6: 129-32, 2011.

De La Mora O, Guerrero S, García V, et al., “Guia de practica clinica diagnóstico y tratamiento de sindrome mielodisplásico”. Catálogo maestro de GPC, Mëxico: 2010

Pintos EN, Carbejo MdR, “Clasificación de los síndromes mielodisplásicos”. Hematología, vol.14, no.3: 86-90, 2010

Tricot GJ, Lauer RC, Appelbaum FR, et al.: Management of the myelodysplastic syndromes. Semin Oncol 14 (4): 444-53, 1987.

Boogaerts MA: Progress in the therapy of myelodysplastic syndromes. Blut 58 (6): 265-70, 1989.

Park S, Grabar S, Kelaidi C, et al.: Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and GCSF: the GFM experience. Blood 111 (2):574-82, 2008.

Mannone L, Gardin C, Quarre MC, et al.: High dose darbepoetin alpha in the treatment of anemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133 (5): 513-9, 2006.

Gabrilove J, Paquette R, Lyons RM, et al.: Phase 2, single-arm trail to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142 (3): 379-93, 2008.

Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al.: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92 (1): 68-75, 1998.

Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A: Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk res 21 (5): 415-25, 1997.

Negrin RS, Stein R, Doherty K, et al.: Maintenance treatment of the anaemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87 (10) 4076-81, 1996.

GreenbergPL, Rigsby CK, Stone RM, et al.: NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw 7 (suppl 9): S1-16, 2009.

Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: Data from the Dusseldorf MDS-registry. Leuk Res.2011;35:1591-1596.


Download data is not yet available.


How to Cite
Raja, K., Gupte, Y., Godhiwala, P., Sonawane, S., Gaidhane, S., Kumar, S., & Zahiruddin, Q. (2020). Fatal Case Of Solid Organ Infarcts In a Case Of Myelodysplastic Syndrome (MDS) With Refractory Anaemia. European Journal of Medical and Health Sciences, 2(3). https://doi.org/10.24018/ejmed.2020.2.3.230